ST. JOSEPH, Mo. (Aug. 11, 2008) – Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces that it has received approval from the U.S. Animal and Plant Health Inspection Service to market the Ingelvac^® CircoFLEX-MycoFLEX^TM combination package to protect pigs against both porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.

With the Ingelvac CircoFLEX-MycoFLEX combination package, its contents, Ingelvac CircoFLEX^® and Ingelvac MycoFLEX,^® can be mixed and administered as a single-dose, 2mL injection to pigs 3 weeks of age or older, which saves time, labor and stress on pigs. Both vaccines contain ImpranFLEX™, the proprietary aqueous-based polymer adjuvant that helps promote quick, long-lasting immunity while reducing the risk of systemic and injection site reactions often associated with other adjuvants.

Ingelvac CircoFLEX-MycoFLEX has been proven effective as an aid in prevention of porcine circovirus type 2 (PCV2) and enzootic pneumonia caused by Mycoplasma hyopneumoniae. Both Ingelvac CircoFLEX and Ingelvac MycoFLEX are non-viscous, highly syringable, single-dose vaccines. Numerous studies show that vaccinating pigs for these diseases can significantly decrease mortality and improve pig performance through growing-finishing.

According to Randy Buller, brand manager for BIVI, Ingelvac CircoFLEX-MycoFLEX gives producers the ability to more conveniently and effectively vaccinate pigs at weaning against two major swine diseases that impact production. “The vaccines deliver greater flexibility in vaccination timing and the highest level of efficacy in disease protection, while reducing stress to pigs and producers,” Robertson says. “Early, effective disease protection translates into reduced mortality, increased pig performance and greater production for producers.”

For more information on Ingelvac CircoFLEX-MycoFLEX vaccine, contact your veterinarian or Boehringer Ingelheim Vetmedica, Inc., at 800-325-9167.